Health ❯ Healthcare ❯ Pharmaceuticals ❯ Weight Loss

Wegovy

New Trials Show Daily Pills Can Help Maintain Weight Loss After GLP-1 Injections

The findings point to a shift toward long-term care that favors simple daily tablets for maintaining results.

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

India Tightens Oversight of GLP-1 Drugs as Semaglutide Generics Proliferate

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

BMJ Review Flags Rapid Weight Regain After GLP‑1 Stop as UK Approves Higher‑Dose Wegovy

Amazon Pharmacy Adds FDA-Approved Wegovy Pill With $25 Copays and Nationwide Delivery

Weight Returns Quickly After Stopping GLP-1 Drugs, Oxford Review Finds

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

FDA-Cleared Wegovy Pill Becomes First Oral GLP-1 for Weight Loss

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Novo Nordisk Files for 7.2 mg Wegovy Dose After Stronger Weight-Loss Results

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

UK Regulator Probes Pancreatitis Cases Linked to GLP-1 Weight-Loss Drugs

Novo Nordisk Launches Wegovy Weight-Loss Drug in India